Shiru’s Post

What a week. Within less than two weeks of ProteinDiscovery.AI's launch, we’ve already attracted global interest, licensing offers, and requests for new functions and custom solutions. The needs of our industry are real and simmering: - Clearly defined IP, which leads to transparent deal structures - A true marketplace that fosters competitive tension, enabling better solutions to scale faster - A fast and powerful way to interrogate the world of natural proteins for safe & scalable solutions for regulated markets Change is here, and I’m so inspired by all the people who are part of it. Let’s keep it going. #disrupt #ai #bioeconomy #platformasaservice #innovation Shiru

“AI-assisted bacterial fermentation advances Alzheimer’s drug” I absolutely love seeing these use cases! We have so much growth potential when we embrace all these great technologies in our era! How is your organization leveraging AI to accelerate your product/service development?

Today we highlight the fifth and final principle from the recently published position paper from EuropaBio - the European Association for Bioindustries and the 17 other signatories. “Apply #innovation Principles within R&D priorities for #biotechnology (including digital and AI advancement), enhance intellectual property protection and develop skills to accelerate industrial transition and production through innovation.” ➡️ Read the rest of the principles here https://lnkd.in/e9-22rRs

🚀 Exciting News! 🚀 Kaggle has launched a new competition: Predict New Medicines with BELKA! Join this groundbreaking challenge to apply your skills in data science and predictive modeling to revolutionize drug discovery. 💊🔬 🌟 What is BELKA? BELKA is an innovative platform that leverages advanced AI algorithms to predict the efficacy and safety of new medicines, accelerating the drug discovery process. 🏆 Competition Details: Participants will have the opportunity to analyze a unique dataset and develop predictive models to identify potential new medicines. The top performers will win exciting prizes and the chance to collaborate with leading researchers in the field. 📅 Save the Date: The competition is live now on Kaggle. Don't miss this chance to showcase your skills, make a real impact in healthcare, and be part of a groundbreaking initiative! 🔗 Register now and learn more: [https://lnkd.in/gBB3rj6J] #Kaggle #DataScience #DrugDiscovery #BELKA #Competition #Innovation #Healthcare #AI #PredictiveModeling

At the core of our AI + Empirical Discovery Engine is our distinctive, miniaturized screening technology thats been foundational to 1859 since its inception in 2019. Our Darwin Platform leverages patented screening technologies to generate high-quality, empirical datasets at scale, enabling robust AIML models to accelerate drug discovery from Hit ID through Lead Optimization. Our Platform: ✅ Integrates rapidly synthesized, drug-like libraries ✅ Conducts activity-based screens in dose-response with high replicates ✅ Produces 1M+ new datapoints per week with <50 mL of reagents ✅ Augments AIML with high-quality training data enriched with SAR Check out platform in action! #drugdiscovery #screening #HitID #LeadID #technology #highthroughput #artificialintelligence #machinelearning #smallmolecules

Are you still using traditional research methods that are linear, rigid, and lack diversity? At the DIA Annual Meeting, stop by our Innovation Theatre presentation hosted by Rich Gliklich to learn how you can revolutionize prospective studies with a flexible, reusable design and continuous streams of #RWD. Dr. Gliklich has extensive experience in the regulatory field, and is a co-author of Agency for Healthcare Research and Quality (#AHRQ) “Registries for Evaluating Patient Outcomes: A User’s Guide". 📍Not attending the meeting? Send us a message 📩 (info@om1.com) for more insights. #DIA2024 #Regulatory #BioPharma #BioTech #LifeSciences #ClinicalResearch #AI

Expectations of life sciences companies today include faster innovation, transparent drug pricing, and a greater purpose beyond profits. In this paper, KPMG US' Alison Little and Mike Ricci examine four primary signals of change and four strategic imperatives that represent the future of life sciences. Read more below. #KPMGHCLS #lifesciences

Expectations of life sciences companies today include faster innovation, transparent drug pricing, and a greater purpose beyond profits. In this paper, KPMG US' Alison Little and Mike Ricci examine four primary signals of change and four strategic imperatives that represent the future of life sciences. Read more below. #KPMGHCLS #lifesciences